Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

6.405 -0.155 (-2.36%)

Streaming Delayed Price Updated: 11:10 AM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ

July 28, 2022

From ImmunityBio

Via Business Wire

7 Best Pharmaceutical Stocks to Buy Now ↗

July 20, 2022

These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.

Via InvestorPlace

ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

June 06, 2022

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Expects To Submit US Application For VesAnktiva In Bladder Cancer This Month ↗

April 04, 2022

ImmunityBio Inc (NASDAQ: IBRX)

Via Benzinga

ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

May 23, 2022

From ImmunityBio, Inc.

Via Business Wire

7 Cheap Biotech Stocks to Buy Now ↗

May 19, 2022

These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains.

Via InvestorPlace

ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

April 28, 2022

From ImmunityBio, Inc.

Via Business Wire

99 Biggest Movers From Yesterday ↗

May 12, 2022

Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.

Via Benzinga

ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

April 25, 2022

From ImmunityBio, Inc.

Via Business Wire

Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

April 21, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from...

Via FinancialNewsMedia

ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

April 01, 2022

From ImmunityBio, Inc.

Via Business Wire

Bonds Are Screaming “Recession.” That’s Great News For One Top Sector. ↗

March 29, 2022

The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession.

Via InvestorPlace

Development of Novel Innovative Diagnostic tests Generating Huge Revenue Opportunity for Global Blood Testing Market

February 16, 2022

Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years....

Via FinancialNewsMedia

ImmunityBio's Ankitva Shows 100% Survival At Two Years In Bladder Cancer Setting ↗

February 15, 2022

ImmunityBio Inc (NASDAQ: IBRX) announced data from its bladder cancer trial (QUILT-3.032) Phase 2/3 study of intravesical BCG plus Anktiva (N-803). The data showed...

Via Benzinga

ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility

February 15, 2022

From ImmunityBio, Inc.

Via Business Wire

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗

February 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...

Via Benzinga

ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer

February 14, 2022

From ImmunityBio, Inc.

Via Business Wire

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗

February 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

16 Stocks Moving in Tuesday's Pre-Market Session ↗

February 01, 2022

Gainers ObsEva SA (NASDAQ: OBSV) rose 22.2% to $1.87 in pre-market trading after the company announced a corporate update, including an increase in share capital on...

Via Benzinga

ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy

January 31, 2022

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial ↗

January 19, 2022

ImmunityBio Inc (NASDAQ: IBRX) has revealed early results from its Phase 2 metastatic pancreatic cancer trial (QUILT 88), showing that patients' overall...

Via Benzinga

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data ↗

January 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)...

Via Benzinga

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival

January 18, 2022

From ImmunityBio, Inc.

Via Business Wire

The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week ↗

January 16, 2022

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss...

Via Benzinga

ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness

January 12, 2022

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Awarded Seminal Patent on Natural Killer Cells

January 04, 2022

From ImmunityBio, Inc.

Via Business Wire

61 Biggest Movers From Yesterday ↗

January 04, 2022

Gainers Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa...

Via Benzinga

Amyris, ImmunityBio Shares Trading Higher On COVID-19 Vaccine Joint Venture ↗

January 03, 2022

Amyris Inc (NASDAQ: AMRS) and ImmunityBio (NASDAQ: IBRX) have completed their previously announced joint venture agreement to accelerate the...

Via Benzinga

45 Biggest Movers From Yesterday ↗

December 29, 2021

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares climbed 64.8% to close at $19.02 on Tuesday as traders circulated a social media post on a potential short squeeze. ShiftPixy...

Via Benzinga

25 Stocks Moving In Tuesday's Mid-Day Session ↗

December 28, 2021

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 64.6% to $18.99 as traders circulated a social media post on a potential short squeeze. Flotek Industries, Inc. (NYSE...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

All News about ImmunityBio, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today